Mindful Yoga for Postpartum Depression

March 13, 2025 updated by: LIN Jingxia Jessie, The Hong Kong Polytechnic University

The Effects of a Mindful Yoga Program on Mood Symptoms and Stress for Postpartum Women With Depressive Symptoms: a Randomized Controlled Clinical Trial

This is a parallel-group randomized controlled trial. A total of 198 postpartum women with depressive symptoms (EPDS scores≥8 at baseline) will be recruited and randomized into two groups: 10-week mindful yoga intervention and 10-week psychoeducation program. Clinical assessment of depression, self-report questionnaires and salivary cortisol tests will be performed at baseline, after 10-week intervention, and at 6-month and 12-month follow-ups. The investigators expected that the mindful yoga intervention will reduce depression after 10 weeks compared to psychoeducation. The mindful yoga intervention will further reduce anxiety, stress, improve quality of life and sleep, and steepen diurnal cortisol slopes. These effects will be maintained for at least six months.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

198

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Postpartum women aged 18-60 years old.
  • The scores of EPDS ≥ 10.
  • At least 6 week and up to 1 year after childbirth.
  • Giving birth to a single full-term healthy baby (gestation between 37-41 weeks, body weight > 2.5kg, APGAR score at 5 minutes > 7).
  • Fewer than 10 hours of yoga/Qi gong/Tai Chi or mindfulness/meditation practice in the previous 3 months.

Exclusion Criteria:

  • Severe complications after delivery, or their infants are admitted to NICU.
  • Regular psychiatric follow-up.
  • Currently taking antipsychotic drugs.
  • Known pragnancy, or other contraindications to physical exercise (e.g., wound healing situation) according to the body examination by O&G clinicians at 6 weeks after delivery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mindful yoga group
The participants in experimental group will receive a 10-week mindfulness-based yoga program, one session per week with 1.5 hours in each session.
The intervention includes mindfulness-based components and yoga practice. Once a week for 10 weeks, with 1.5 hours in each session (30 minutes mindfulness-based practice and 1 hour yoga practice). A well-trained research personnel will facilitate the mindfulness-based section, and a qualified yoga instructor will facilitate the yoga section.
Active Comparator: Psychoeducation group
The participants in the psychoeducation group will receive a 10-week psychoeducation program, one session per week with 1.5 hours in each session.
Knowledge of perinatal mental health, stress-related management, postnatal nutrition, exercise habit and sleep hygiene will be provided to the participants in the psychoeducation group. It is a group-based intervention delivered in hybrid mode including face-to-face and online group-based class. Once a week for 10 weeks, with 1.5 hour in each session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Edinburgh Postnatal Depression Scale
Time Frame: Baseline, 10 weeks, 6 months and 1 year follow-ups.
Measures postnatal depression. Each item scores 0-3, and the total score ranges from 0 to 30. Higher score means worse depressive symptoms.
Baseline, 10 weeks, 6 months and 1 year follow-ups.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Depression Anxiety Stress Scale-Depression
Time Frame: Baseline, 10 weeks, 6 months and 1 year follow-ups.
Measures depressive symptoms. Each item scores 0-3, the total score for depression ranges from 0 to 21. Higher score means worse symptoms of depression.
Baseline, 10 weeks, 6 months and 1 year follow-ups.
Depression Anxiety Stress Scale-Anxiety
Time Frame: Baseline, 10 weeks, 6 months and 1 year follow-ups.
Measures anxiety symptoms. Each item scores 0-3, the total score for anxiety ranges from 0 to 21. Higher score means worse symptoms of anxiety.
Baseline, 10 weeks, 6 months and 1 year follow-ups.
Depression Anxiety Stress Scale-Stress
Time Frame: Baseline, 10 weeks, 6 months and 1 year follow-ups.
Measures stress symptoms. Each item scores 0-3, the total score for stress ranges from 0 to 21. Higher score means worse symptoms of stress.
Baseline, 10 weeks, 6 months and 1 year follow-ups.
Pittsburgh Sleep Quality Index
Time Frame: Baseline, 10 weeks, 6 months and 1 year follow-ups.
Measures sleep quality. There are 8 components scores, and each component score ranges from 0 to 3. Higher score means worse sleep quality.
Baseline, 10 weeks, 6 months and 1 year follow-ups.
36 Item-Short Form Health Survey Questionnaire
Time Frame: Baseline, 10 weeks, 6 months and 1 year follow-ups.
Measures quality of life including physical and mental health. Each item scores 0-100. There are eight subscores ranging from 0 to 100. Higher score means better quality of life.
Baseline, 10 weeks, 6 months and 1 year follow-ups.
Five Facet Mindfulness Questionnaire
Time Frame: Baseline, 10 weeks, 6 months and 1 year follow-ups.
Measures the level of mindfulness ability. Each item scores 1-5, and the total score ranges from 42 to 210. Higher score means better mindfulness ability.
Baseline, 10 weeks, 6 months and 1 year follow-ups.
Pregnancy Symptom Inventory
Time Frame: Baseline, 10 weeks, 6 months and 1 year follow-ups.
Measures physical pain and fatigue of postpartum women. Each item scores 0-3. The total score ranges from 0 to 24. Higher score means worse pregnancy symptoms.
Baseline, 10 weeks, 6 months and 1 year follow-ups.
Cortisol concentration level
Time Frame: Baseline and 10 weeks (post-intervention).
Measures salivary cortisol concentration at baseline and post-intervention. Higher concentration means higher level of stress and depression.
Baseline and 10 weeks (post-intervention).
Physical fitness
Time Frame: Baseline and 10 weeks (post-intervention).
6-minute walking test is used for physical fitness measure. The total distance walked during 6 minutes is recorded. Higher score means better fitness.
Baseline and 10 weeks (post-intervention).
Balance
Time Frame: Baseline and 10 weeks (post-intervention).
Single-leg standing test is used to measure the balance. The time to keep the posture is recorded. Higher score means better balance ability.
Baseline and 10 weeks (post-intervention).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Jessie LIN, PhD, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 8, 2021

Primary Completion (Estimated)

July 15, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

January 17, 2024

First Submitted That Met QC Criteria

February 15, 2024

First Posted (Actual)

February 23, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 13, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HMRF17182481

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe